Hepatitis C Virus Non-structural protein 3-5B (HCV NS3-5B) (HCV NS3-5B)

The target refers to the Hepatitis C Virus (HCV) non-structural protein complex, comprising NS3, NS4A, NS4B, NS5A, and NS5B, which is a primary focus for T-cell mediated immunotherapy. In the context of vaccine development, a genetically inactivated version of this polyprotein, known as NSmut, is utilized to elicit robust CD4+ and CD8+ T cell responses. This NSmut immunogen contains a mutated NS5B polymerase to prevent viral replication while preserving the antigenic epitopes necessary for immune recognition. T cell receptors (TCRs) recognize specific peptides derived from these proteins when they are presented by Major Histocompatibility Complex (MHC) molecules on the surface of infected hepatocytes or antigen-presenting cells. Therapeutic strategies targeting this interaction include viral vector vaccines, such as ChAd3-NSmut and MVA-NSmut, and adoptive T cell therapies using TCR-engineered T cells like those employing the HCV1406 TCR. These approaches aim to overcome the high genetic variability of HCV by targeting conserved regions within the non-structural proteins. Monitoring efficacy often involves measuring antigen-specific T cell frequencies and cytokine production, such as interferon-gamma. Potential safety concerns include immune-mediated hepatotoxicity and off-target effects if the engineered TCRs cross-react with self-peptides.

Other names

HCV NSmutHCV non-structural polyproteinNS3-NS5B polyproteinHCV NS3-5B complexHCV NSmut antigen

Vaccine-induced T cell activation; TCR-mediated recognition of viral peptide-MHC complexes leading to lysis of infected cells; Inhibition of viral protease, helicase, or polymerase activity.